{
  "id": "5c55d9b707647bbc4b000009",
  "type": "factoid",
  "question": "Which molecule is targeted by Caplacizumab?",
  "ideal_answer": "Caplacizumab is anti-von Willebrand factor (VWF) antibody that blocks the interaction between VWF and platelets. It is used for treatment of acquired thrombotic thrombocytopenic purpura (aTTP).",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/23307200",
    "http://www.ncbi.nlm.nih.gov/pubmed/29209322",
    "http://www.ncbi.nlm.nih.gov/pubmed/29807376",
    "http://www.ncbi.nlm.nih.gov/pubmed/28139813",
    "http://www.ncbi.nlm.nih.gov/pubmed/28445600",
    "http://www.ncbi.nlm.nih.gov/pubmed/28110841",
    "http://www.ncbi.nlm.nih.gov/pubmed/28645643",
    "http://www.ncbi.nlm.nih.gov/pubmed/30298461",
    "http://www.ncbi.nlm.nih.gov/pubmed/30046703",
    "http://www.ncbi.nlm.nih.gov/pubmed/26863353"
  ],
  "snippets": [
    {
      "text": "Caplacizumab, a nanobody that blocks the interaction between VWF and platelets, has shown promising results in decreasing the time to recover from the acute events that will hopefully translate into long-term clinical benefit for patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30046703",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ablynx, a Sanofi Company, has developed the anti-von Willebrand factor Nanobody\u00ae caplacizumab (Cablivi\u2122) for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30298461",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Promising agents under evaluation include N-acetylcysteine, bortezomib, recombinant ADAMTS13 and caplacizumab, an inhibitor of the glycoprotein-Ib/IX-von Willebrand factor axis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28110841",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The most promising candidates for future treatment of TTP are: rituximab for termination of the autoimmune process, caplacizumab for prevention of platelet-VWF-interaction, and recombinant ADAMTS13 for replacement of the inhibited or missing enzyme.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28139813",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Promising agents under evaluation include caplacizumab (an inhibitor of the glycoprotein-Ib/IX-Von-Willebrand factor axis), N-acetylcysteine, recombinant ADAMTS13, and anti-plasmocyte compounds.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28645643",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " In the phase II TITAN study, treatment with caplacizumab, an anti-von Willebrand factor Nanobody\u00ae was shown to reduce the time to confirmed platelet count normalization and exacerbations during treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28445600",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "It is now anticipated that the first VHH-based antibody drug, Caplacizumab, a bivalent anti-vWF antibody for treating rare blood clotting disorders, may be approved and commercialized in 2018 or shortly thereafter.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29209322",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Daily plasma exchange and immunosuppressive therapies induce remission, but mortality and morbidity due to microthrombosis remain high.<br><b>METHODS</b>: Caplacizumab, an anti-von Willebrand factor humanized single-variable-domain immunoglobulin (Nanobody), inhibits the interaction between ultralarge von Willebrand factor multimers and platelets.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26863353",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "von Willebrand factor"
}